Literature DB >> 26896122

Long-Term Comparison of Simultaneous Topography-Guided Photorefractive Keratectomy Followed by Corneal Cross-linking versus Corneal Cross-linking Alone.

Georgios A Kontadakis1, Vardhaman P Kankariya2, Konstantinos Tsoulnaras2, Aristofanis I Pallikaris2, Argyro Plaka2, George D Kymionis3.   

Abstract

PURPOSE: To compare the results of corneal collagen cross-linking (CXL) alone with combined simultaneous topography-guided photorefractive keratectomy plus CXL (tPRK-CXL) for progressive keratoconus for a 3-year interval.
DESIGN: Prospective, comparative interventional case series. PARTICIPANTS: Forty-eight patients (60 eyes) with progressive keratoconus.
METHODS: Thirty eyes underwent combined tPRK with a solid-state laser (maximum ablation depth, 50 μm) followed by CXL, and 30 eyes underwent CXL alone. Groups were matched in terms of age and keratoconus stage. MAIN OUTCOME MEASURES: Corrected distance visual acuity (CDVA), uncorrected distance visual acuity (UDVA), keratometry, and corneal confocal microscopy.
RESULTS: Mean follow up was 39±11 months. Mean age at operation was 28±5.82 years. Before surgery, average CDVA in the tPRK-CXL group was 0.26±0.17 logarithm of the minimum angle of resolution (logMAR), and in the CXL group was 0.24±0.18 logMAR (P = 0.58). At last follow-up, CDVA was 0.09±0.10 logMAR in the tPRK-CXL group and 0.15±0.12 logMAR in the CXL group (P < 0.05). In both groups, no patient lost more than 2 lines of Snellen visual acuity, whereas 19 eyes and 8 eyes in the tPRK-CXL group and in the CXL group, respectively, gained 2 or more lines of CDVA. Before surgery, average UDVA was 0.83±0.54 logMAR in the tPRK-CXL group and 0.86±0.62 logMAR in the CXL group (P = 0.79). At last follow-up, UDVA was 0.27±0.25 logMAR in the tPRK-CXL group and 0.69±0.58 logMAR in the CXL group (P < 0.001). Before surgery, steep and flat keratometry had no significant differences between groups, and at last follow-up, both steep and flat keratometry readings were significantly flatter in the tPRK-CXL group compared with the CXL group. Depth of CXL treatment, as evaluated by confocal microscopy, was 269.8±31.8 μm in the CXL group and 299.7±29.8 μm in the tPRK-CXL group (P < 0.001). No differences were found in endothelial cell density.
CONCLUSIONS: Simultaneous tPRK followed by CXL in this series of keratoconus patients offered significantly improved vision to treated patients in comparison with CXL alone, and similar results regarding postoperative stability. Safety concerns regarding corneal thickness were taken into account in treatment planning.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26896122     DOI: 10.1016/j.ophtha.2016.01.010

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  15 in total

Review 1.  Surgical Options for the Refractive Correction of Keratoconus: Myth or Reality.

Authors:  L Fernández-Vega-Cueto; V Romano; R Zaldivar; C H Gordillo; F Aiello; D Madrid-Costa; J F Alfonso
Journal:  J Ophthalmol       Date:  2017-12-18       Impact factor: 1.909

2.  Evaluation of the Effectiveness of Cross-Linking Combined With Photorefractive Keratectomy for Treatment of Keratoconus.

Authors:  Mohammed Iqbal; Ahmed Elmassry; Ahmed Tawfik; Mervat Elshabrawy Elgharieb; Osama Mohiey El Deen Al Nahrawy; Ashraf Hassan Soliman; Hisham A Saad; Hosam A Ibrahim Elzembely; Ahmed Mohamed Saeed; Osama Ali Mohammed; Ahmed Gad Kamel; Islam Saad El Saman
Journal:  Cornea       Date:  2018-09       Impact factor: 2.651

3.  One-Year Efficacy and Safety of Combined Photorefractive Keratectomy and Accelerated Corneal Collagen Cross-Linking after Intacs SK Intracorneal Ring Segment Implantation in Moderate Keratoconus.

Authors:  Il Hwan Koh; Kyoung Yul Seo; Seong Bae Park; Hun Yang; InSik Kim; Jin Sun Kim; David G Hwang; Sang Min Nam
Journal:  Biomed Res Int       Date:  2019-07-08       Impact factor: 3.411

Review 4.  Updates on Managements for Keratoconus.

Authors:  Mehrdad Mohammadpour; Zahra Heidari; Hassan Hashemi
Journal:  J Curr Ophthalmol       Date:  2017-12-06

5.  Simultaneous Transepithelial Topography-Guided Photorefractive Keratectomy and Accelerated Cross-Linking in Keratoconus: 2-Year Follow-Up.

Authors:  Sibel Ahmet; Alper Ağca; Dilek Yaşa; Ahmet Alperen Koç; Mesut Toğaç; Yusuf Yıldırım; Burçin Kepez Yıldız; Ahmet Demirok
Journal:  Biomed Res Int       Date:  2018-10-15       Impact factor: 3.411

6.  Late onset corneal haze after corneal cross-linking for progressive keratoconus.

Authors:  Vasilios Peponis; Loukas Kontomichos; Irini Chatziralli; George Kontadakis; Efstratios Parikakis
Journal:  Am J Ophthalmol Case Rep       Date:  2019-02-26

7.  Standard cross-linking versus photorefractive keratectomy combined with accelerated cross-linking for keratoconus management: a comparative study.

Authors:  Mohammed Iqbal; Ahmed Elmassry; Ahmed Tawfik; Mervat Elgharieb; Khaled Nagy; Ashraf Soliman; Hisham Saad; Tarek Tawfik; Osama Ali; Ahmed Gad; Islam El Saman; Alaa Radwan; Hosam Elzembely; Amin Abou Ali; Omar Fawzy
Journal:  Acta Ophthalmol       Date:  2018-11-29       Impact factor: 3.761

8.  Changes in higher order aberrations after central corneal regularization - a comparative two-year analysis of a semi-automated topography-guided photorefractive keratectomy combined with corneal cross-linking.

Authors:  Katja C Iselin; Philipp B Baenninger; Lucas M Bachmann; Frank Bochmann; Michael A Thiel; Claude Kaufmann
Journal:  Eye Vis (Lond)       Date:  2020-03-03

9.  Central corneal regularization (CCR): an alternative approach in keratoconus treatment.

Authors:  Giulio Mulè; Shihao Chen; Jia Zhang; Wen Zhou; Vasileios Selimis; Aleksandar Stojanovic; Ioannis M Aslanides
Journal:  Eye Vis (Lond)       Date:  2019-12-16

10.  Long-Term Follow-Up of Combined Photorefractive Keratectomy and Corneal Crosslinking in Keratoconus Suspects.

Authors:  George Kymionis; George Kontadakis; Michael Grentzelos; Myrsini Petrelli
Journal:  Clin Ophthalmol       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.